Eric Souied Joins SeaBeLife - Scorecard - MDSpire

Eric Souied Joins SeaBeLife

French biotechnology company, SeaBeLife, welcomes AMD specialist to its scientific committee

  • March 9, 2026

  • 2 min

Share

Clinical Scorecard: Eric Souied Joins SeaBeLife

At a Glance

CategoryDetail
ConditionAge-Related Macular Degeneration (AMD)
Key MechanismsInhibition of necroptosis and ferroptosis
Target PopulationIndividuals with geographic atrophy (GA) associated with AMD
Care SettingOphthalmology clinics and research settings

Key Highlights

  • Professor Eric Souied appointed to SeaBeLife's scientific committee
  • Focus on dual-pathway strategy targeting retinal degeneration
  • SBL03 shows preclinical efficacy in geographic atrophy
  • GA affects an estimated eight million people worldwide
  • Limited treatment options available in Europe

Guideline-Based Recommendations

Diagnosis

  • Identify genetic polymorphisms associated with AMD
  • Assess for geographic atrophy in early-stage disease

Management

  • Implement disease-modifying approaches targeting necroptosis and ferroptosis

Monitoring & Follow-up

  • Regular assessments of retinal health and progression of GA

Risks

  • Progressive loss of retinal pigment epithelium and photoreceptors

Patient & Prescribing Data

Patients with geographic atrophy due to AMD

Focus on addressing underlying drivers of degeneration

Clinical Best Practices

  • Utilize a mechanistic approach to understand retinal degeneration
  • Incorporate lipid metabolism and oxidative stress in treatment strategies
  • Engage in regulatory strategy and trial design for new therapies

Related Resources & Content

Original Source(s)

Eric Souied Joins SeaBeLife

  • March 9, 2026

Related Content

Educating Patients on IOL Options Is Key

Stone Oak Ophthalmology Center strives to provide an environment in which patients fully understand their options and feel confident with their IOL choices.

FDA Approves Lucentis Biosimilar Nufymco

Ranibizumab-leyk (Nufymco) is approved for all Lucentis indications.

FDA Rejects Extended Dosing Intervals for Eylea HD

The agency did not agree with Regeneron’s proposal to add dosing intervals greater than every 16 weeks, the maximum interval currently indicated for aflibercept 8 mg injections.